XML 15 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Revenues:        
Royalties $ 15,698 $ 9,755 $ 39,842 $ 26,648
Material sales 4,219 6,046 13,445 20,456
License fees, milestones and other revenues 1,702 1,900 17,500 3,618
Total revenues 21,619 17,701 70,787 50,722
Operating costs and expenses:        
Cost of sales [1] 999 1,250 2,674 4,923
Amortization of intangibles 2,706 593 7,912 1,780
Research and development 5,898 1,945 14,813 8,730
General and administrative 6,305 4,971 19,995 18,190
Lease exit and termination costs 245 345 863 786
Total operating costs and expenses 16,153 9,104 46,257 34,409
Income from operations 5,466 8,597 24,530 16,313
Other (expense) income:        
Interest expense, net (3,116) (2,930) (9,172) (8,875)
Increase (decrease) in contingent liabilities (958) 2,301 (2,595) (4,976)
Gain on deconsolidation of Viking Therapeutics 0 0 0 28,190
Loss from Viking Therapeutics (1,396) (2,169) (14,139) (3,040)
Other income, net 1,215 1,485 2,107 1,889
Total other (expense) income, net (4,255) (1,313) (23,799) 13,188
Income before income taxes 1,211 7,284 731 29,501
Income tax benefit (expense) (160) 191,881 28 191,602
Income from operations 1,051 199,165 759 221,103
Gain on sale of Oncology Product Line before income taxes 0 0 1,139 0
Income tax expense on discontinued operations 0 0 (408) 0
Income from discontinued operations 0 0 731 0
Net income including noncontrolling interests: 1,051 199,165 1,490 221,103
Less: Net loss attributable to noncontrolling interests 0 0 0 (2,380)
Net income $ 1,051 $ 199,165 $ 1,490 $ 223,483
Basic earnings per share data(2)        
Income from continuing operations (in usd per share) [2] $ 0.05 $ 10.01 $ 0.04 $ 11.32
Income from discontinued operations (in usd per share) [2] 0.00 0.00 0.04 0.00
Net income (in usd per share) [2] 0.05 10.01 0.07 11.32
Diluted earnings per share data (2)        
Income from continuing operations (in usd per share) [2] 0.05 9.28 0.03 10.58
Income from discontinued operations (in usd per share) [2] 0.00 0.00 0.03 0.00
Net (loss) income (in usd per share) $ 0.05 [2] $ 9.28 [2] $ 0.07 $ 10.58 [2]
Shares used for computation (in thousands)        
Basic (in shares) 20,887,000 19,887,000 20,806,000 19,741,000
Diluted (in shares) 22,997,279 21,459,648 22,742,249 21,121,972
[1] Excludes amortization of intangibles.
[2] The sum of net income per share amounts may not equal the totals due to rounding